-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 11, 2025

Optimizing Treatment Sequencing in Advanced Colorectal Cancer

Author(s)Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA , Melody Chang, RPh, MBA, BCOP, Nicholas Bouchard, PharmD

Experts discuss additional factors considered when determining the most effective sequence of therapies for metastatic colorectal cancer, including fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab, and explore the further research needed to understand optimal sequencing of these treatments better.

Episodes in this series

EP. 1 Treatment Options in mCRC: A Clinical Overview

EP. 1 Treatment Options in mCRC: A Clinical Overview

EP. 2 Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP. 2 Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP. 3 Quality of Life and Patient Outcomes in mCRC Treatment

EP. 3 Quality of Life and Patient Outcomes in mCRC Treatment

EP. 4 Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP. 4 Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP. 5 The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP. 5 The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP. 6 Evolution of Oncology Pharmacy Practice in mCRC

EP. 6 Evolution of Oncology Pharmacy Practice in mCRC

EP. 7 Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP. 7 Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP. 8 Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP. 8 Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP. 9 Best Practices for Overcoming mCRC Prior Authorization Barriers

EP. 9 Best Practices for Overcoming mCRC Prior Authorization Barriers

EP. 10 Building Better Collaboration: Reducing Care Delays in Managing mCRC

EP. 10 Building Better Collaboration: Reducing Care Delays in Managing mCRC

Video content above is prompted by the following:

What additional factors do you consider when determining the most effective sequence of these therapies (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab)?
What further research is needed to understand optimal sequencing of these therapies better?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Screening, Risk Stratification, and the Multidisciplinary Care Model for MASH

ByNadege Gunn, MD

June 30th 2026

Experts featured in this series.

Beyond Brand vs. Generic: What Really Drives Treatment Decisions After Repeated Failures

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 30th 2026 | Updated: June 16th 2026

MASH in Focus: How Patient Awareness, Clinical Empowerment, and Research Have Transformed the Field

ByNadege Gunn, MD

June 30th 2026

Experts featured in this series.

When Treatment Isn't Working: Defining Failure and Charting the Next Steps in Psychiatric Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 30th 2026 | Updated: June 16th 2026

Diagnosing and Assessing Atopic Dermatitis: Tools, Scoring Systems, and Patient-Centered Goal Setting

ByAngela J. Lamb, MD

June 29th 2026

Trending on AJMC

COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD

Longer Sleep Linked to Lower Glycemic Variability, Reduced Deviation Risk in Adolescents

Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer